$8.86
0.566.75%
At close: -
$8.96
0.11.10%
After Hours: 7:43 PM EDT
Comments
Loading...
INmune Bio Analyst Ratings and Price Targets | NASDAQ:INMB | Benzinga
INmune Bio Inc has a consensus price target of $18.29 based on the ratings of 7 analysts. The high is $30 issued by Maxim Group on February 13, 2025. The low is $7 issued by B. Riley Securities on May 24, 2022. The 3 most-recent analyst ratings were released by Maxim Group, Scotiabank, and Alliance Global Partners on February 13, 2025, February 11, 2025, and October 21, 2024, respectively. With an average price target of $24.33 between Maxim Group, Scotiabank, and Alliance Global Partners, there's an implied 171.65% upside for INmune Bio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Maxim Group
Scotiabank
Alliance Global Partners
Raymond James
Baird
1calculated from analyst ratings
Analyst Ratings for INmune Bio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/13/2025 | Buy Now | 234.91% | Maxim Group | Jason McCarthy42% | $22 → $30 | Maintains | Buy | Get Alert |
| 02/11/2025 | Buy Now | 156.77% | Scotiabank | George Farmer48% | $22 → $23 | Maintains | Sector Outperform | Get Alert |
| 10/21/2024 | Buy Now | 123.28% | Alliance Global Partners | James Molloy30% | → $20 | Initiates | → Buy | Get Alert |
| 09/27/2024 | Buy Now | 100.95% | Raymond James | — | → $18 | Initiates | → Outperform | Get Alert |
| 08/22/2024 | Buy Now | 145.6% | Scotiabank | George Farmer48% | → $22 | Initiates | → Sector Outperform | Get Alert |
| 06/01/2023 | Buy Now | 78.62% | Baird | Joel Beatty69% | → $16 | Initiates | → Outperform | Get Alert |
| 05/24/2022 | Buy Now | 56.29% | BTIG | Thomas Shrader43% | $31 → $14 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | -21.85% | B. Riley Securities | Mayank Mamtani71% | $14 → $7 | Downgrade | Buy → Neutral | Get Alert |
FAQ
What is the target price for INmune Bio (INMB) stock?
The latest price target for INmune Bio (NASDAQ:INMB) was reported by Maxim Group on February 13, 2025. The analyst firm set a price target for $30.00 expecting INMB to rise to within 12 months (a possible 234.91% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for INmune Bio (INMB)?
The latest analyst rating for INmune Bio (NASDAQ:INMB) was provided by Maxim Group, and INmune Bio maintained their buy rating.
When was the last upgrade for INmune Bio (INMB)?
There is no last upgrade for INmune Bio
When was the last downgrade for INmune Bio (INMB)?
The last downgrade for INmune Bio Inc happened on May 24, 2022 when B. Riley Securities changed their price target from $14 to $7 for INmune Bio Inc.
When is the next analyst rating going to be posted or updated for INmune Bio (INMB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of INmune Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for INmune Bio was filed on February 13, 2025 so you should expect the next rating to be made available sometime around February 13, 2026.
Is the Analyst Rating INmune Bio (INMB) correct?
While ratings are subjective and will change, the latest INmune Bio (INMB) rating was a maintained with a price target of $22.00 to $30.00. The current price INmune Bio (INMB) is trading at is $8.96, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.